Browsing Tag
uniQure
5 posts
uniQure’s epilepsy data could test whether its gene therapy platform can expand beyond Huntington’s disease
Find out how uniQure’s AMT-260 epilepsy data could shape QURE stock sentiment and its broader neurology gene therapy strategy.
uniQure surges 78% as FDA clears accelerated approval path for its Huntington’s disease gene therapy
uniQure (QURE) surges 78 percent as FDA clears accelerated approval path for AMT-130 in Huntington's disease, with BLA filing due Q3 2026. Full analysis.
uniQure (QURE, NASDAQ) targets Q3 BLA after FDA’s Huntington’s reversal
The FDA spent months blocking uniQure's Huntington's gene therapy. Now it wants the filing in Q3. QURE doubled, but approval is still unwon.
Five-year durability data show Hemgenix is transforming haemophilia B care with a single dose
Five‑year results show Hemgenix delivers long‑lasting bleed protection and stable clotting factor levels for haemophilia B patients. Read more on the breakthrough here.
CSL Behring bags Hemgenix EC approval for treatment of Hemophilia B
German-based biotechnology company CSL Behring has received conditional marketing authorization (CMA) from the European Commission (EC) for its…